A Phase I/IIb Study of DEC205mAb-NY-ESO-1 Fusion Protein (CDX-1401) Given With Adjuvant Poly-ICLC in Combination With INCB024360 for Patients in Remission With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Whose Tumors Express NY-ESO-1 or LAGE-1 Antigen
Phase of Trial: Phase I/II
Latest Information Update: 02 Apr 2018
At a glance
- Drugs Epacadostat (Primary) ; CDX 1401; Poly ICLC
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 29 Mar 2018 Planned End Date changed from 12 Jun 2019 to 12 Feb 2021.
- 29 Mar 2018 Planned primary completion date changed from 12 Jun 2018 to 12 Feb 2020.
- 19 Feb 2018 Planned End Date changed from 12 Feb 2019 to 12 Jun 2019.